{"id":46226,"date":"2022-07-15T13:01:53","date_gmt":"2022-07-15T11:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/"},"modified":"2022-07-15T13:01:53","modified_gmt":"2022-07-15T11:01:53","slug":"elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/","title":{"rendered":"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382721\/elastase-inhibitor-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=x97gff&amp;utm_campaign=1726728+-+Elastase+Inhibitor+Drugs+Pipeline+Insights+Report+2022+Featuring+AstraZeneca%2C+Polyphor%2C+Bayer+HealthCare%2C+ParinGenix%2C+%26+Proteo+Biotech&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221;<\/a> clinical trials has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220715005223\/en\/1514913\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220715005223\/en\/1514913\/21\/logo.jpg\"><\/a><\/p>\n<p>\n&#8220;Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Elastase Inhibitor development.\n<\/p>\n<p>\nThe report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.\n<\/p>\n<p>\n<strong>Descriptive coverage of pipeline development activities for Elastase Inhibitor<\/strong>\n<\/p>\n<p>\nPipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&amp;D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.\n<\/p>\n<p>\n<strong>Pipeline Therapeutics assessment of products for Elastase Inhibitor<\/strong>\n<\/p>\n<p>\nThe report assesses the active Elastase Inhibitor pipeline products by developmental stage, product type, molecule typ\n<\/p>\n<p>\ne, and administration route.\n<\/p>\n<p>\n<strong>Scope of the Report<\/strong>\n<\/p>\n<ul>\n<li>\nProvides a snapshot of the therapeutics pipeline activity for Elastase Inhibitor\n<\/li>\n<li>\nFeatures the Elastase Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages\n<\/li>\n<li>\nOffers detailed therapeutic product profiles of Elastase Inhibitor with key coverage of developmental activities including licensing &amp; collaboration deals, patent details, designations, technologies, indications and chemical information\n<\/li>\n<li>\nTherapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration\n<\/li>\n<li>\nCoverage of dormant and discontinued pipeline projects across Elastase Inhibitor\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Report Introduction<\/strong>\n<\/p>\n<p>\n<strong>2. Elastase Inhibitor &#8211; Overview<\/strong>\n<\/p>\n<p>\n<strong>3. Pipeline Therapeutics<\/strong>\n<\/p>\n<ul>\n<li>\nAn Overview of Pipeline Products for Elastase Inhibitor\n<\/li>\n<\/ul>\n<p>\n<strong>4. Comparative Analysis<\/strong>\n<\/p>\n<p>\n<strong>5. Elastase Inhibitor Pipeline Products in Clinical Stages<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>6. Elastase Inhibitor Pipeline Products in Non-clinical Stages<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>7. Therapeutic Assessment: Active Products<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Assessment by Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Stage and Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Molecule Type\n<\/li>\n<li>\nPipeline Assessment by Stage and Molecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>8. Inactive Pipeline Products<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<li>\nReason for dormancy\/discontinuation\n<\/li>\n<\/ul>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nAstraZeneca\n<\/li>\n<li>\nPolyphor\n<\/li>\n<li>\nBayer HealthCare\n<\/li>\n<li>\nParinGenix\n<\/li>\n<li>\nProteo Biotech\n<\/li>\n<\/ul>\n<p>\nFor more information about this clinical trials report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382721\/elastase-inhibitor-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=x97gff&amp;utm_campaign=1726728+-+Elastase+Inhibitor+Drugs+Pipeline+Insights+Report+2022+Featuring+AstraZeneca%2C+Polyphor%2C+Bayer+HealthCare%2C+ParinGenix%2C+%26+Proteo+Biotech&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/jmcyzs<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"mailto&#58;&#112;&#114;&#101;&#115;&#115;&#64;&#x72;&#x65;&#x73;&#x65;&#x61;&#x72;&#x63;&#x68;&#x61;&#x6e;&#x64;&#x6d;arkets&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#114;e&#x73;&#x73;&#64;r&#x65;&#x73;&#101;a&#x72;&#99;h&#x61;&#x6e;&#100;m&#x61;&#x72;&#107;e&#x74;&#115;&#46;&#x63;&#x6f;&#109;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Elastase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46226","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Elastase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-15T11:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220715005223\/en\/1514913\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-07-15T11:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/\"},\"wordCount\":412,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005223\\\/en\\\/1514913\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/\",\"name\":\"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005223\\\/en\\\/1514913\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-07-15T11:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005223\\\/en\\\/1514913\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005223\\\/en\\\/1514913\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Elastase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-15T11:01:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220715005223\/en\/1514913\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech &#8211; ResearchAndMarkets.com","datePublished":"2022-07-15T11:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/"},"wordCount":412,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005223\/en\/1514913\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/","name":"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005223\/en\/1514913\/21\/logo.jpg","datePublished":"2022-07-15T11:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220715005223\/en\/1514913\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220715005223\/en\/1514913\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/elastase-inhibitor-drugs-pipeline-insights-report-2022-featuring-astrazeneca-polyphor-bayer-healthcare-paringenix-proteo-biotech-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Elastase Inhibitor Drugs Pipeline Insights Report 2022 Featuring AstraZeneca, Polyphor, Bayer HealthCare, ParinGenix, &amp; Proteo Biotech &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46226"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46226\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}